mRNA Cancer Vaccine Market Report 2026-2036: 27.1% CAGR
21 April 2026.
Visiongain’s latest report, mRNA Cancer Vaccine Market Report 2026-2036, provides detailed forecasts and strategic analysis across vaccine type, therapeutic approach, development phase, indication, and end-user segments, alongside technology trends, trade dynamics, and competitive positioning.
The global mRNA cancer vaccine market is projected to grow from US$1,288.1 million in 2026 at a CAGR of 27.1% through to 2036, reflecting strong expansion driven by clinical validation, ecosystem development, and increasing investment in personalised oncology solutions.
The market is expected to see significant value creation as precision medicine adoption accelerates, supported by advances in genomic profiling, neoantigen targeting, and scalable mRNA manufacturing platforms.
Key Market Insights
The global mRNA cancer vaccine market will expand rapidly through 2036 at a CAGR of 27.1%
Growth is driven by clinical validation, strategic partnerships, and ecosystem expansion
Key regions: North America, Europe, Asia Pacific
Leading companies: BioNTech, Moderna, Arcturus Therapeutics, Sana Biotechnology
Key trend: Integration of personalised mRNA therapies into precision oncology pathways
Download Free Sample Report (incl. forecasts, market data, and methodology)
Late-stage clinical success is significantly reducing development risk and strengthening commercial confidence in mRNA cancer vaccines. Programmes such as mRNA-4157 (V940) have demonstrated strong efficacy in reducing recurrence risk in melanoma, supporting progression into Phase III trials and expanding into additional indications.
Collaborations between biotech firms and large pharmaceutical companies are accelerating development timelines and improving commercial readiness. Partnerships such as Moderna and Merck combine mRNA innovation with established immunotherapy assets, enhancing clinical execution and global market access.
Technology & Innovation
Expansion of the mRNA Ecosystem
The rapid development of the mRNA ecosystem, including lipid nanoparticle providers, CDMOs, and AI-driven biotech firms, is improving scalability and reducing production bottlenecks. Investments in manufacturing infrastructure and platform technologies are enabling faster clinical development and supporting long-term commercialisation.
Trade & Supply Chain Dynamics
Global trade dynamics are increasingly influencing the mRNA cancer vaccine market, particularly through tariffs on critical inputs such as lipid nanoparticles, nucleotides, and specialised enzymes.
The market depends on globally integrated supply chains, exposing manufacturers to tariff-related cost increases and procurement challenges. In the short term, this may lead to higher production costs and delayed timelines, while longer-term effects may include increased localisation of manufacturing.
Commercial Impact:
Cost pressure: Rising input costs are increasing production expenses, particularly for personalised vaccines
Supply chain shifts: Greater focus on domestic manufacturing and diversified sourcing
Margin implications: Higher costs may impact pricing and reimbursement dynamics
Competitive positioning: Companies with integrated supply chains and scalable platforms are better positioned
Increasing collaborations, funding rounds, and acquisitions are accelerating innovation and pipeline development. High-value partnerships and investments are strengthening platform capabilities and enabling broader clinical expansion.
Evolution of Value-Based Pricing Models
The shift towards outcome-based reimbursement is improving the commercial viability of high-cost personalised therapies. These models align payment with clinical outcomes, supporting wider adoption and improving patient access over time.
Competitive Landscape
The major players operating in the mRNA cancer vaccine market include:
Arcturus Therapeutics
BioNTech
Chimeron Bio
eTheRNA
Ethris GmbH
ImmuneSensor Therapeutics
Moderna
Orna Therapeutics
Replimune Group
These companies are focusing on partnerships, R&D investment, and platform innovation to strengthen their market positions and accelerate clinical development.
Recent Developments
January 2026 – Acuitas Therapeutics acquired a majority stake in RNA Technologies & Therapeutics to strengthen RNA-LNP development capabilities
August 2025 – Strand Therapeutics raised US$153 million in Series B funding to advance its mRNA oncology pipeline
May 2025 – ST Pharm reported strong preclinical results for its mRNA vaccine candidate VER-001, validating its platform technology
Frequently Asked Questions
What is driving growth in the mRNA cancer vaccine market? Growth is driven by clinical validation, precision oncology adoption, and strategic partnerships accelerating development and commercialisation.
How are trade and supply chain dynamics affecting the market? Tariffs and global sourcing dependencies are increasing costs and creating supply chain complexity, particularly for specialised inputs.
Who are the leading companies in the market? Key players include BioNTech, Moderna, Arcturus Therapeutics, and Sana Biotechnology.
Download Free Sample Report (incl. forecasts, market data, and methodology)
Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.
